相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characteristics of second breast events among women treated with breast-conserving surgery for DCIS in the community
Michael J. Hassett et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Increased CD4 and CD8-positive T cell infiltrate signifies good prognosis in a subset of triple-negative breast cancer
Hirofumi Matsumoto et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Protective effect of naturally occurring anti-HER2 autoantibodies on breast cancer
Yukiko Tabuchi et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
The immune system and hormone-receptor positive breast cancer: Is it really a dead end?
Maria Vittoria Dieci et al.
CANCER TREATMENT REVIEWS (2016)
A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice
Thi Tran et al.
CLINICAL CANCER RESEARCH (2016)
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice
Stefanie N. Linch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Tumor-infiltrating lymphocytes in breast cancer predict the response to chemotherapy and survival outcome: A meta-analysis
Ke Wang et al.
ONCOTARGET (2016)
CD8+ tumor-infiltrating lymphocytes contribute to spontaneous healing in HER2-positive ductal carcinoma in situ
Michi Morita et al.
CANCER MEDICINE (2016)
Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
Edith A. Perez et al.
JAMA ONCOLOGY (2016)
Association of Depressed Anti-HER2 T-Helper Type 1 Response With Recurrence in Patients With Completely Treated HER2-Positive Breast Cancer Role for Immune Monitoring
Jashodeep Datta et al.
JAMA ONCOLOGY (2016)
T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells
Prachi Namjoshi et al.
Oncotarget (2016)
Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial
Edith A. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Better Together: Targeted Combination Therapies in Breast Cancer
Elisa Zanardi et al.
SEMINARS IN ONCOLOGY (2015)
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration
Tiziana Triulzi et al.
ONCOTARGET (2015)
CD4+ T-Helper Type 1 Cytokines and Trastuzumab Facilitate CD8+ T-cell Targeting of HER2/neu-Expressing Cancers
Jashodeep Datta et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Rationale for a multimodality strategy to enhance the efficacy of dendritic cell-based cancer immunotherapy
Jashodeep Datta et al.
FRONTIERS IN IMMUNOLOGY (2015)
Progressive loss of anti-HER2 CD4+ T-helper type 1 response in breast tumorigenesis and the potential for immune restoration
Jashodeep Datta et al.
ONCOIMMUNOLOGY (2015)
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab A Secondary Analysis of the NeoALTTO Trial
Roberto Salgado et al.
JAMA ONCOLOGY (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
HER2-family signalling mechanisms, clinical implications and targeting in breast cancer
N. Elster et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest
Nicolas Acquavella et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Anti-HER2 CD4+ T-helper type 1 response is a novel immune correlate to pathologic response following neoadjuvant therapy in HER2-positive breast cancer
Jashodeep Datta et al.
BREAST CANCER RESEARCH (2015)
Advances and Future Directions in the Targeting of HER2-positive Breast Cancer: Implications for the Future
Ishwaria M. Subbiah et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2014)
CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
Hye-Jung Kim et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Antigen-pulsed CpG-ODN-activated dendrtic cells induce host-protective immune response by regulating the T regulatory cell functioning in Leishmania donovani-infected mice: critical role of CXCL10
Saikat Majumder et al.
FRONTIERS IN IMMUNOLOGY (2014)
Anti-HER2/Neu passive-aggressive immunotherapy
Eric D. Mortenson et al.
ONCOIMMUNOLOGY (2014)
Circulating Type-1 anti tumor CD4+ T cells are preferentially pro-apoptotic in cancer patients
Amy K. Wesa et al.
FRONTIERS IN ONCOLOGY (2014)
Dendritic Cell Cancer Vaccines: From the Bench to the Bedside
Tamar Katz et al.
RAMBAM MAIMONIDES MEDICAL JOURNAL (2014)
Therapeutic Considerations When Treating HER2-positive Metastatic Breast Cancer
Ciara C. O'Sullivan et al.
CURRENT BREAST CANCER REPORTS (2014)
Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
M. M. Kim et al.
ANNALS OF ONCOLOGY (2013)
Blockade of PD-1/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice
Yan Ge et al.
CANCER LETTERS (2013)
Dendritic cells process synthetic long peptides better than whole protein, improving antigen presentation and T-cell activation
Rodney A. Rosalia et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Abnormal T regulatory cells (Tregs: FOXP3+, CTLA-4+), myeloid-derived suppressor cells (MDSCs: monocytic, granulocytic) and polarised T helper cell profiles (Th1, Th2, Th17) in women with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC) and surgery: failure of abolition of abnormal treg profile with treatment and correlation of treg levels with pathological response to NAC
Chandan Verma et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
T-helper-1-cell cytokines drive cancer into senescence
Heidi Braumueller et al.
NATURE (2013)
Inhibition of CD4+CD25+Regulatory T Cell Function and Conversion into Th1-Like Effectors by a Toll-Like Receptor-Activated Dendritic Cell Vaccine
Major K. Lee et al.
PLOS ONE (2013)
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Elizabeth A. Mittendorf et al.
CANCER (2012)
HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ
Anupama Sharma et al.
CANCER (2012)
Dendritic cell-based vaccines: barriers and opportunities
Jessica A. Cintolo et al.
FUTURE ONCOLOGY (2012)
Targeting Stat3 Induces Senescence in Tumor Cells and Elicits Prophylactic and Therapeutic Immune Responses against Breast Cancer Growth Mediated by NK Cells and CD4+ T Cells
Mercedes Tkach et al.
JOURNAL OF IMMUNOLOGY (2012)
A Novel Dendritic Cell-based Immunization Approach for the Induction of Durable Th1-polarized Anti-HER-2/neu Responses in Women With Early Breast Cancer
Gary K. Koski et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Combined vaccine plus axitinib therapy yields superior antitumor efficacy in a murine melanoma model
Anamika Bose et al.
MELANOMA RESEARCH (2012)
The Promise of Antibody-Drug Conjugates
Beverly A. Teicher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Devika Gajria et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
T cell recognition of HLA-A2 restricted tumor antigens is impaired by the oncogene HER2
Kousaku Mimura et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology
Suzanne A. Eccles
INTERNATIONAL JOURNAL OF DEVELOPMENTAL BIOLOGY (2011)
Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups
Michael Untch et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
Sahar M. A. Mahmoud et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion Vaccine
Jacalyn Rosenblatt et al.
JOURNAL OF IMMUNOTHERAPY (2011)
The Significance of HER-2/neu Receptor Positivity and Immunophenotype in Ductal Carcinoma In Situ with Early Invasive Disease
Shuko Harada et al.
JOURNAL OF SURGICAL ONCOLOGY (2011)
CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene Inactivation
Kavya Rakhra et al.
CANCER CELL (2010)
CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T Lymphocytes
Rinke Bos et al.
CANCER RESEARCH (2010)
Depletion of CD4+CD25+regulatory T cells enhances natural killer T cell-mediated anti-tumour immunity in a murine mammary breast cancer model
H. Hong et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni et al.
LANCET (2010)
HER-2/neu Overexpression as a Predictor for the Transition from In situ to Invasive Breast Cancer
Robert E. Roses et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
Werner Scheuer et al.
CANCER RESEARCH (2009)
The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From US Military Cancer Institute Clinical Trials Group Study I-01 and I-02
Linda C. Benavides et al.
CLINICAL CANCER RESEARCH (2009)
Resistance to Trastuzumab in Breast Cancer
Paula R. Pohlmann et al.
CLINICAL CANCER RESEARCH (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The E75 HER2/neu peptide vaccine
Elizabeth A. Mittendorf et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Immunological decision-making: how does the immune system decide to mount a helper T-cell response?
Gerard E. Kaiko et al.
IMMUNOLOGY (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Regulatory T cells and tumour immunity - observations in mice and men
Awen Gallimore et al.
IMMUNOLOGY (2008)
Lapatinib plus capecitabine for HER2-positive advanced breast cancer
Charles E. Geyer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Depletion of CD4+CD25+ regulatory T cells promotes a tumor-specific immune response in pancreas cancer-bearing mice
Carsten T. Viehl et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer
Elizabeth A. Mittendorf et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Activation-induced cell death limits effector function of CD4 tumor-specific T cells
RR Saff et al.
JOURNAL OF IMMUNOLOGY (2004)
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination
N Casares et al.
JOURNAL OF IMMUNOLOGY (2003)
Expression of the HERI-4 family of receptor tyrosine kinases in breast cancer
CJ Witton et al.
JOURNAL OF PATHOLOGY (2003)
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
UK Liyanage et al.
JOURNAL OF IMMUNOLOGY (2002)
HER2/neu in the management of invasive breast cancer
F Meric et al.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS (2002)
分享论文
